An open label, parallel group, Phase III clinical study in patients with advanced prostate cancer suitable for hormonal manipulation to demonstrate the non-inferiority of a new three-month Novosis Goserelin 10.8 mg implant versus the reference product Zoladex 10.8 mg and to show the comparability of the Novosis Goserelin 3.6 mg implant applied every 28 days for three months with the new three-month Novosis Goserelin 10.8 mg implant.

Trial Profile

An open label, parallel group, Phase III clinical study in patients with advanced prostate cancer suitable for hormonal manipulation to demonstrate the non-inferiority of a new three-month Novosis Goserelin 10.8 mg implant versus the reference product Zoladex 10.8 mg and to show the comparability of the Novosis Goserelin 3.6 mg implant applied every 28 days for three months with the new three-month Novosis Goserelin 10.8 mg implant.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Goserelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top